Algernon gets FDA nod for human study of Ifenprodil for COVID-19
Algernon has received the FDA’s approval for the commencement of a Phase 2 and 3 human study of it’s repurposed
Read moreAlgernon has received the FDA’s approval for the commencement of a Phase 2 and 3 human study of it’s repurposed
Read moreAstraZeneca is going to expedite the development of the University of Oxford investigational COVID-19 vaccine with a $1 billion BARDA
Read morePfizer Inc. has revealed revised clinical Phase 1b results on PF-06939926, an investigational gene therapy to treat Duchenne muscular dystrophy
Read moreNubilaria, a forward thinking clinical data management company, has released an important announcement for Researchers and Health Professionals in Europe
Read moreNew post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read moreUK-headquartered AstraZeneca and Oxford University announced an agreement to develop and distribute the university’s future recombinant adenovirus vaccine to prevent
Read moreJapanese research-driven pharmaceutical company Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. announced on April 28 that the
Read moreRemdesivir, an investigational nucleotide analog with broad-spectrum antiviral activity developed by the Californian biopharmaceutical company Gilead Sciences, has shown promising
Read moreNubilaria is providing it’s innovative ACTide EDC system free in support of a clinical study for COVID-19 related ARDS intensive
Read moreThe first intermediate analysis of the Phase I Zika vaccine candidate sample (mRNA-1893) reveals that the dosage levels of 10
Read more